Advanced Search

Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 1998 December;133(6) > Giornale Italiano di Dermatologia e Venereologia 1998 December;133(6):459-63



A Journal on Dermatology and Sexually Transmitted Diseases

Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014

Frequency: Bi-Monthly

ISSN 0392-0488

Online ISSN 1827-1820


Giornale Italiano di Dermatologia e Venereologia 1998 December;133(6):459-63


Short-term treatment with calcipotriol in chronic psoriasis

Colombo R., Soltani S.

Ospedale Dermatologico S. Lazzaro - Torino, II Divisione

Background. The aim of the study is to demonstrate the efficacy and safety of topic calcipotriol (ointment) after a 3 month therapy.
Methods. Study design: open, uncontrolled study without follow-up. Patients: 29 patients, both males and females, aged between 25 and 77, affected by inveterate psoriasis with chronic stable psoriatic plaques, had been selected. During the study, the patients have not undergone any systemic therapy, either intralesional or RUV in the two months preceding the treatment. All patients presented normal values of calcemia and creatinemia. Treatment: calcipotriol ointment was administered in a twice daily regimen on the lesions, excluding those localized on face, scalp, and genitalia. The efficacy has been evaluated with the “Psoriasis Area Severity Index” (PASI). The patients were photographed at the 1st visit, and then every 15, 30, 60, 90 days. At every visit, besides PASI, erythema, desquamation, infiltration and pustulation parameters were also evaluated, according to a score range from 0 to 3 (absent, mild, moderate, severe). The subjective impression of the patient was considered as well. With regard to safety evaluation, calcemia, creatinemia and adverse events, if any, were evaluated.
Results. Desquamatory component has shown to be the most sensible to treatment, whereas erythema has been the most resistant. Only one patient discontinued the treatment because of erythema and burning after 15 days. The reduction of PASI, has been similar to that obtained with betamethasone ointment 0.1%, obviously without side-effects. No rebound phenomena were registered.
Conclusions. On the basis of these experimental data, the conclusion is drawn that calcipotriol for topic administration is as efficacious as cortisons; moreover, patients’ compliance improves due to the better tolerability.

language: Italian


top of page